These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 22282697)

  • 1. Treatment of hemophilia: a review of current advances and ongoing issues.
    Coppola A; Di Capua M; Di Minno MN; Di Palo M; Marrone E; Ieranò P; Arturo C; Tufano A; Cerbone AM
    J Blood Med; 2010; 1():183-95. PubMed ID: 22282697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges.
    Coppola A; Tagliaferri A; Di Capua M; Franchini M
    Semin Thromb Hemost; 2012 Feb; 38(1):79-94. PubMed ID: 22314606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Stobart K; Iorio A; Wu JK
    Cochrane Database Syst Rev; 2006 Apr; (2):CD003429. PubMed ID: 16625581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Stobart K; Iorio A; Wu JK
    Cochrane Database Syst Rev; 2005 Apr; (2):CD003429. PubMed ID: 15846666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.
    Chai-Adisaksopha C; Nevitt SJ; Simpson ML; Janbain M; Konkle BA
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011441. PubMed ID: 28944952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
    Fischer K; Valentino L; Ljung R; Blanchette V
    Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of bleeding in hemophilia patients with high-titer inhibitors.
    Leissinger CA; Konkle BA; Antunes SV
    Expert Rev Hematol; 2015 Jun; 8(3):375-82. PubMed ID: 25937074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hemophilia B: focus on recombinant factor IX.
    Franchini M; Frattini F; Crestani S; Sissa C; Bonfanti C
    Biologics; 2013; 7():33-8. PubMed ID: 23430394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
    Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
    Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central venous access devices in patients with hemophilia.
    Valentino LA; Kapoor M
    Expert Rev Med Devices; 2005 Nov; 2(6):699-711. PubMed ID: 16293097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in Hemophilia A Management.
    Cho S; Perry AM; Cheng AM; Wang C; Rico JF
    Adv Pediatr; 2022 Aug; 69(1):133-147. PubMed ID: 35985706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of secondary prophylaxis in children with severe hemophilia.
    Manco-Johnson MJ; Nuss R; Geraghty S; Funk S; Kilcoyne R
    Am J Hematol; 1994 Oct; 47(2):113-7. PubMed ID: 8092125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Iorio A; Marchesini E; Marcucci M; Stobart K; Chan AK
    Cochrane Database Syst Rev; 2011 Sep; (9):CD003429. PubMed ID: 21901684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward optimal therapy for inhibitors in hemophilia.
    Kempton CL; Meeks SL
    Blood; 2014 Nov; 124(23):3365-72. PubMed ID: 25428222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylaxis in congenital hemophilia with inhibitors: the role of recombinant activated factor VII.
    Franchini M; Manzato F; Salvagno GL; Montagnana M; Zaffanello M; Lippi G
    Semin Thromb Hemost; 2009 Nov; 35(8):814-9. PubMed ID: 20169518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward optimal therapy for inhibitors in hemophilia.
    Kempton CL; Meeks SL
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):364-71. PubMed ID: 25696880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Articular Bleeding in Hemophilia.
    Rodriguez-Merchan EC
    Cardiovasc Hematol Disord Drug Targets; 2016; 16(1):21-24. PubMed ID: 28049407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.